表紙
市場調查報告書
商品編碼
601992

多發性硬化症:流行病學的預測

Multiple Sclerosis -Epidemiology Forecast to 2028

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 50 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球多發性硬化症的流行病學的預測相關分析,提供疾病概要和目前治療手法/演算法,全球整體及主要國家 (美國·歐洲各國·日本) 的患病人數趨勢預測 (總計12年份),男女·各年齡·各子類型等詳細趨勢,今後的市場機會·醫藥品開發預測等相關調查。

第1章 簡介

第2章 多發性硬化症的流行病學:市場概要

  • 多發性硬化症的患者人口 (最新值·預測值)

第3章 疾病的背景情況和概要

  • 簡介
  • 風險要素
  • 病因
  • 症狀
  • 病理形成
  • EDSS (神經症狀評估標準)

第4章 流行病學和患者人口

  • 分析的要點
  • 患者人口與預測參數
  • 多發性硬化症的患病人數: (7MM)主要7個國家
  • 多發性硬化症的患病人數: (7MM)主要7個國家,各地區
  • 多發性硬化症的患病人數: (7MM)主要7個國家,分佈結構 (最新值)
  • 多發性硬化症的患病人數: (7MM)主要7個國家,分佈結構 (預測值)

第5章 多發性硬化症的流行病學

第6章 美國

  • 前提條件與合理的理由
  • 多發性硬化症的患病人數
  • 多發性硬化症的患病人數:男女
  • 多發性硬化症的患病人數:各子類型
  • 多發性硬化症的患病人數:各年齡層
  • 多發性硬化症的患病人數:EDSS評分

第7章 德國

第8章 法國

第9章 義大利

第10章 西班牙

第11章 英國

第12章 日本

第13章 未滿足需求

第14章 附錄

第15章 分析方法

  • 資訊來源

第16章 諮詢服務

第17章 免責聲明

第18章 關於DelveInsight

目錄
Product Code: DIEI0322

DelveInsight's "Multiple Sclerosis - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Multiple Sclerosis epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Multiple Sclerosis Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Multiple Sclerosis in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Multiple Sclerosis outlook. It also includes the explanation of changing trends of epidemiology outlining the Multiple Sclerosis scenario.

Multiple Sclerosis Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Multiple Sclerosis thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

  • The report covers detailed overview of Multiple Sclerosis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Multiple Sclerosis Report assesses the disease risk and burden and highlights the unmet needs
  • It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Total Cases in Multiple Sclerosis

Key assessments

  • Patient Segmentation in Multiple Sclerosis
  • Multiple Sclerosis Risk & Burden
  • Factors driving growth in a specific Multiple Sclerosis patient population

Table of Contents

1. Report Introduction

2. Multiple Sclerosis Epidemiology Overview at a Glance

  • 2.1. Patient Share Distribution of Multiple Sclerosis in 2016
  • 2.2. Patient Share Distribution of Multiple Sclerosis in 2028

3. Disease Background and Overview: Multiple Sclerosis

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Multiple Sclerosis in 7MM
  • 4.3. Total Prevalent/ Incident Patient Population of Multiple Sclerosis in 7MM - By Countries

5. Epidemiology of Multiple Sclerosis by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.1.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.1.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.1.5. Diagnosed Cases of the Multiple Sclerosis
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.4.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.4.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.4.5. Diagnosed Cases of the Multiple Sclerosis
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.5.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.5.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.5.5. Diagnosed Cases of the Multiple Sclerosis
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.6.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.6.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.6.5. Diagnosed Cases of the Multiple Sclerosis
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.7.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.7.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.7.5. Diagnosed Cases of the Multiple Sclerosis
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.8.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.8.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.8.5. Diagnosed Cases of the Multiple Sclerosis
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.9.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.9.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.9.5. Diagnosed Cases of the Multiple Sclerosis

6. Unmet Needs of the Multiple Sclerosis

7. Appendix

8. Report Methodology

  • 8.1. Sources

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

Indication Specific

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Multiple Sclerosis in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Multiple Sclerosis in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Multiple Sclerosis in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Multiple Sclerosis in United States (2016-2028)*
  • Table 5: Sex- Specific Cases of the Multiple Sclerosis in United States (2016-2028)*
  • Table 6: Diagnosed Cases of the Multiple Sclerosis in United States (2016-2028)
  • Table 7: Prevalent/Incident Cases of the Multiple Sclerosis in Germany (2016-2028)
  • Table 8: Sub-Type Specific cases of the Multiple Sclerosis in Germany (2016-2028) *
  • Table 9: Sex- Specific Cases of the Multiple Sclerosis in Germany (2016-2028) *
  • Table 10: Diagnosed Cases of the Multiple Sclerosis in Germany (2016-2028)
  • Table 11: Prevalent/Incident Cases of the Multiple Sclerosis in France (2016-2028)
  • Table 12: Sub-Type Specific cases of the Multiple Sclerosis in France (2016-2028) *
  • Table 13: Sex- Specific Cases of the Multiple Sclerosis in France (2016-2028) *
  • Table 14: Diagnosed Cases of the Multiple Sclerosis in France (2016-2028)
  • Table 15: Prevalent/Incident Cases of the Multiple Sclerosis in Italy (2016-2028)
  • Table 16: Sub-Type Specific cases of the Multiple Sclerosis in Italy (2016-2028) *
  • Table 17: Sex- Specific Cases of the Multiple Sclerosis in Italy (2016-2028) *
  • Table 18: Diagnosed Cases of the Multiple Sclerosis in Italy (2016-2028)
  • Table 19: Prevalent/Incident Cases of the Multiple Sclerosis in Spain (2016-2028)
  • Table 20: Sub-Type Specific cases of the Multiple Sclerosis in Spain (2016-2028) *
  • Table 21: Sex- Specific Cases of the Multiple Sclerosis in Spain (2016-2028) *
  • Table 22: Diagnosed Cases of the Multiple Sclerosis in Spain (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Multiple Sclerosis in UK (2016-2028)
  • Table 24: Sub-Type Specific cases of the Multiple Sclerosis in UK (2016-2028) *
  • Table 25: Sex- Specific Cases of the Multiple Sclerosis in UK (2016-2028) *
  • Table 26: Diagnosed Cases of the Multiple Sclerosis in UK (2016-2028)
  • Table 27: Prevalent/Incident Cases of the Multiple Sclerosis in Japan (2016-2028)
  • Table 28: Sub-Type Specific cases of the Multiple Sclerosis in Japan (2016-2028) *
  • Table 29: Sex- Specific Cases of the Multiple Sclerosis in Japan (2016-2028) *
  • Table 30: Diagnosed Cases of the Multiple Sclerosis in Japan (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Multiple Sclerosis in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Multiple Sclerosis in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Multiple Sclerosis in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Multiple Sclerosis in United States (2016-2028)*
  • Figure 5: Sex- Specific Cases of the Multiple Sclerosis in United States (2016-2028)*
  • Figure 6: Diagnosed Cases of the Multiple Sclerosis in United States (2016-2028)
  • Figure 7: Prevalent/Incident Cases of the Multiple Sclerosis in Germany (2016-2028)
  • Figure 8: Sub-Type Specific cases of the Multiple Sclerosis in Germany (2016-2028) *
  • Figure 9: Sex- Specific Cases of the Multiple Sclerosis in Germany (2016-2028) *
  • Figure 10: Diagnosed Cases of the Multiple Sclerosis in Germany (2016-2028)
  • Figure 11: Prevalent/Incident Cases of the Multiple Sclerosis in France (2016-2028)
  • Figure 12: Sub-Type Specific cases of the Multiple Sclerosis in France (2016-2028) *
  • Figure 13: Sex- Specific Cases of the Multiple Sclerosis in France (2016-2028) *
  • Figure 14: Diagnosed Cases of the Multiple Sclerosis in France (2016-2028)
  • Figure 15: Prevalent/Incident Cases of the Multiple Sclerosis in Italy (2016-2028)
  • Figure 16: Sub-Type Specific cases of the Multiple Sclerosis in Italy (2016-2028) *
  • Figure 17: Sex- Specific Cases of the Multiple Sclerosis in Italy (2016-2028) *
  • Figure 18: Diagnosed Cases of the Multiple Sclerosis in Italy (2016-2028)
  • Figure 19: Prevalent/Incident Cases of the Multiple Sclerosis in Spain (2016-2028)
  • Figure 20: Sub-Type Specific cases of the Multiple Sclerosis in Spain (2016-2028) *
  • Figure 21: Sex- Specific Cases of the Multiple Sclerosis in Spain (2016-2028) *
  • Figure 22: Diagnosed Cases of the Multiple Sclerosis in Spain (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Multiple Sclerosis in UK (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Multiple Sclerosis in UK (2016-2028) *
  • Figure 25: Sex- Specific Cases of the Multiple Sclerosis in UK (2016-2028) *
  • Figure 26: Diagnosed Cases of the Multiple Sclerosis in UK (2016-2028)
  • Figure 27: Prevalent/Incident Cases of the Multiple Sclerosis in Japan (2016-2028)
  • Figure 28: Sub-Type Specific cases of the Multiple Sclerosis in Japan (2016-2028) *
  • Figure 29: Sex- Specific Cases of the Multiple Sclerosis in Japan (2016-2028) *
  • Figure 30: Diagnosed Cases of the Multiple Sclerosis in Japan (2016-2028)